Subject: PSID Up Over 12% on Big Update

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
PSID Up Over 12% on Big Update
Hot Stock to WatchHot Stock to Watch

Company:
PositiveID Corporation (OTCQB: PSID)


Last:

Price: 0.0294

Change (%): + 0.0032 (12.21)

Volume: 1,280,862
PSID Chart

PositiveID Corporation Prepares Additional M-BAND Systems for Field Deployment and Testing

DELRAY BEACH, Fla., Jan. 20, 2015 (GLOBE NEWSWIRE) - PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, announced today that it is preparing additional M-BAND systems for field deployment and testing. Once deployed, the Company will have a total of six M-BAND systems in the field and under evaluation, including the four units delivered to the U.S government during the second half of 2014.

M-BAND (Microfluidic Bio-agent Autonomous Networked Detector) is currently under evaluation with a large federal government contractor to support the U.S. Department of Defense (“DoD”) JUPITR Program. As part of this program, M-BAND is being tested and evaluated to baseline performance, reliability, maintainability, ease of use, and cost of operation to provide the “best of breed” and most affordable options for the U.S. Army and U.S. Air Force. M-BAND currently performs high specificity detection for six organisms and three toxins on the Centers for Disease Control’s category A and B select agents list.

Continue Reading



Momentum Renewed for U.S. Department of Homeland Security’s BioWatch Program

On December 16, 2014, the U.S. Department of Homeland Security (DHS) released a public request for information (RFI) seeking technologies relevant to the automated detection and identification of air-borne biological agents. This release sparks movement for DHS’s efforts to drastically improve the BioWatch Program, which has been slumbering for the past two years. The BioWatch Program was established in 2003, as a means to address the ever-increasing threat of bioterrorism. BioWatch’s goal, according to the DHS is, “to detect the presence of biological agents of concern in a timely manner and identify the target agents with a high degree of confidence.”

Biological Threats
In 2001, on the heels of the 9/11 terror attacks, the public became aware of bio-terrorism after several cases of inhalation anthrax were reported. Twenty-two people became ill after envelopes filled with a white powder containing anthrax spores were mailed to two U.S. Senators. Five of the 22 who came in contact with the envelopes died. While there have been no reports of inhalation anthrax being used as a bio-terrorism agent since 2001, the threat remains strong. The Centers for Disease Control (CDC), rates anthrax as a “Tier 1” threat, meaning its biological agents and toxins present the highest risk for deliberate misuse, possessing the ability to yield mass casualties, cripple the economy and infrastructure, diminish public morale, and cause a severe threat to public health and safety. Anthrax is one of over 40 agents the CDC has on its bio-terrorism watch list.

Continue Reading

Like Us on FacebookFollow Us on Twitter

IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks